Genentech's Avastin Gaining Market Share In On- And Off-Label Indications
This article was originally published in The Pink Sheet Daily
Executive Summary
Avastin's share in the first-line metastatic colorectal cancer setting reached 55% in the fourth quarter, up from 42% in the third quarter. Off-label use in the second-line increased to 41%. An August "Dear Doctor" letter on thromboembolic events may have had an impact on slower-than-expected fourth quarter sales of the oncologic.
You may also be interested in...
Avastin Lung Cancer Reimbursement Will Be Case By Case, Genentech Says
The company says it is too early to determine the extent of off-label use of Avastin in lung cancer. Genentech will present data on use of Avastin alone, as well as in combination with Tarceva, for the treatment of lung cancer at ASCO's annual meeting in May.
Avastin Lung Cancer Reimbursement Will Be Case By Case, Genentech Says
The company says it is too early to determine the extent of off-label use of Avastin in lung cancer. Genentech will present data on use of Avastin alone, as well as in combination with Tarceva, for the treatment of lung cancer at ASCO's annual meeting in May.
Genentech Builds Tarceva Inventory Following Iressa's Failed Trial
Genentech has been building inventory for its non-small cell lung cancer agent Tarceva (erlotinib) following AstraZeneca's announcement that Iressa (gefitinib) failed to show a statistically significant survival benefit